Cargando…
Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial
INTRODUCTION: Cabergoline (CAB) is conventionally started at a dose of 0.25-0.5 mg once a week with dose escalation at 1to 3months intervals. Previously, we and others have shown that rapid escalation and high doses of CAB can lead to normalization of serum PRL as early as 8.2 weeks in 93% of the pa...
Autores principales: | Rastogi, Ashu, Walia, Rama, Dutta, Pinaki, Bhansali, Anil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603052/ https://www.ncbi.nlm.nih.gov/pubmed/23565404 http://dx.doi.org/10.4103/2230-8210.104064 |
Ejemplares similares
-
Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
por: Walia, Rama, et al.
Publicado: (2011) -
Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas
por: Paepegaey, Anne-Cécile, et al.
Publicado: (2017) -
Cabergoline therapy for Macroprolactinoma during pregnancy: A case report
por: Shahzad, Hira, et al.
Publicado: (2012) -
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
por: Lee, Youngki, et al.
Publicado: (2014) -
A macroprolactinoma becoming resistant to cabergoline and developing
atypical pathology
por: Sbardella, Emilia, et al.
Publicado: (2016)